Pre-Admission Hyperglycemia and Its Effect on Morbidity and Mortality
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by North Shore Long Island Jewish Health System.
Recruitment status was Active, not recruiting
Information provided by:
North Shore Long Island Jewish Health System
First received: March 26, 2009
Last updated: March 27, 2009
Last verified: March 2009
It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.
||Observational Model: Cohort
Time Perspective: Prospective
||To Evaluate if Pre-Admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||July 2010 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older and speech English that give consent.
- All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older and speech English that give consent.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00871832
|Staten Island University Hospital
|Staten Island, New York, United States, 10305 |
Staten Island University Hospital
No publications provided
||Mario Castellanos, MD, Staten Island University Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 26, 2009
||March 27, 2009
||United States: Institutional Review Board
Keywords provided by North Shore Long Island Jewish Health System:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 16, 2013
Glucose Metabolism Disorders